Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
University of California, San Francisco
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
Stanford University
University of Miami
Bayside Health
Bayside Health
National Cancer Institute (NCI)
Stanford University
Istituto Clinico Humanitas
Children's Oncology Group
Children's Oncology Group
Istituto Clinico Humanitas